Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01215968
First received: October 5, 2010
Last updated: October 3, 2014
Last verified: October 2014
  Purpose

The primary purpose of this Study is to help answer the following research question(s).

  • How does LY2189265 affect gastric emptying (the speed at which food and drink leaves the stomach) in patients with Type 2 diabetes?
  • How does LY2189265 affect how the body handles metformin (a drug used to treat Type 2 diabetes)?
  • Is LY2189265 safe and are any side effects associated with it?

The study will be participant-blind in Week 1, and participant- and investigator-blind from Week 2 through Week 5.

Each participant will receive placebo on Week 1 and once-weekly doses of LY2189265 or Placebo on Weeks 2 to 5. Participants taking metformin for the treatment of Type 2 Diabetes Mellitus (T2DM) will continue taking metformin as part of the study.


Condition Intervention Phase
Diabetes Mellitus, Type 2
Biological: LY2189265
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Study to Evaluate the Effect of LY2189265 on Gastric Emptying Using Scintigraphy in Patients With Type 2 Diabetes Mellitus

Resource links provided by NLM:


Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • Time Required for 50% of Radioactivity To Be Emptied From the Stomach by Scintigraphy [ Time Frame: Days 3, 10,17, 24 and 31 ] [ Designated as safety issue: No ]
    After at least 8 hours fasting, participants received a radiolabeled breakfast containing technetium-99m-tin colloid (99mTc-tin colloid). After which serial anterior and posterior scintigraphy images were taken. Data presented are the time required for 50% of radioactivity to be emptied from stomach. The results presented are Geometric Least Squares (LS) Mean. LS Mean values were controlled for weeks.


Secondary Outcome Measures:
  • Area Under the Curve (AUC) of Metformin [ Time Frame: Days 3, 17 and 31 ] [ Designated as safety issue: No ]
    Metformin was used as a secondary marker in the study to correlate the effect of LY2189265 on gastric emptying to the pharmacokinetics (PK) (measured as AUC) of concomitant medications. Participants taking metformin for treatment of Type 2 Diabetes Mellitus (T2DM) underwent PK assessments for metformin in parallel to their scintigraphy assessments for gastric emptying. AUC of metformin was calculated during one dosing interval.

  • Maximum Concentration (Cmax) of Metformin [ Time Frame: Days 3, 17 and 31 ] [ Designated as safety issue: No ]
    Metformin was used as a secondary marker in the study to correlate the effect of LY2189265 on gastric emptying to the pharmacokinetics (PK) (measured as Cmax) of concomitant medications. Participants taking metformin for treatment of Type 2 Diabetes Mellitus (T2DM) underwent PK assessments for metformin in parallel to their scintigraphy assessments for gastric emptying.

  • Time to Maximum Concentration (Tmax) of Metformin [ Time Frame: Days 3, 17 and 31 ] [ Designated as safety issue: No ]
    Metformin was used as a secondary marker in the study to correlate the effect of LY2189265 on gastric emptying to the pharmacokinetics (PK) (measured as Tmax) of concomitant medications. Participants taking metformin for treatment of Type 2 Diabetes Mellitus (T2DM) underwent PK assessments for metformin in parallel to their scintigraphy assessments for gastric emptying.

  • Number of Participants With Clinically Significant Effects [ Time Frame: Baseline through 5 weeks ] [ Designated as safety issue: Yes ]
    Adverse events (AEs) were considered clinically significant effects. A summary of serious adverse events (SAEs) and other nonserious AEs are located in the Reported Adverse Event section.


Enrollment: 38
Study Start Date: September 2010
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo

Each participant will receive placebo on Week 1. Participants randomized to placebo will receive once-weekly doses of placebo on Weeks 2 to 5.

Placebo will be administered by single subcutaneous injection into the skin of the abdominal wall.

Participants regularly taking metformin will continue their normal dosing regimen throughout the study.

Drug: Placebo
Administered subcutaneously
Experimental: LY2189265

Participants randomized to LY2189265 will receive once-weekly doses of LY2189265 on Weeks 2 to 5.

1.5 milligram (mg) LY2189265 will be administered by single subcutaneous injection into the skin of the abdominal wall.

Participants regularly taking metformin will continue their normal dosing regimen throughout the study.

Biological: LY2189265
1.5 mg administered subcutaneously
Drug: Placebo
Administered subcutaneously

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Are males or females, diagnosed with Type 2 Diabetes Mellitus for greater than or equal to 3 months prior to screening.
  2. Male patients agree to use a reliable method of birth control during the study and for 3 months following the last dose of study drug. Female patients must be of non-child-bearing potential due to surgical sterilization or menopause.
  3. Have a body mass index (BMI) between 18.5 and 40.0 kilogram/square meter (kg/m²), inclusive.
  4. Have Type 2 Diabetes Mellitus controlled with diet and exercise alone or are stable on a single oral antidiabetic medication (e.g. metformin) prior to screening, and have been taking a stable dose for >7 days prior to the first dosing occasion.
  5. Have a fasting blood glucose value at screening >126 milligram/deciliter (mg/dL) (7.0 [millimoles/liter] mmol/L) for patients on a controlled diet, and >108 mg/dL (6.0 mmol/L) for patients on oral antidiabetic medication, with an upper limit of 180 mg/dL (approximately 9.9 mmol/L) in each case.
  6. Have a hemoglobin A1c (HbA1c) (indicates what your average blood glucose level has been in the past 3 months) value at screening (or within 4 weeks prior to screening) of 6.5% to 9.5%. If HbA1c is between 6.1% and 6.5%, patients may participate in the study providing they are receiving permissible oral antidiabetic medication.
  7. Have clinical laboratory test results within normal ranges as determined by the study doctor.
  8. Can provide enough blood in order to undergo the blood sampling required for the study.
  9. Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
  10. Have signed the consent form approved by Lilly and the Ethical Review Board (ERB) governing the site.

    Exclusion Criteria:

  11. Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
  12. Have previously been exposed to, or have known allergies to glucagon-like-peptide-1 (GLP-1)-related compounds including LY2189265.
  13. Are persons who have previously completed or withdrawn from this study or any other study investigating LY2189265 or have received glucagon-like peptides or incretin mimetics in the past 3 months.
  14. Have taken certain Type 2 Diabetes medications within 30 days prior to screening.
  15. Have an abnormality in the electrocardiogram (ECG) performed at screening.
  16. Have poorly controlled high blood pressure (systolic blood pressure >160 millimeters of mercury [mmHg] and/or diastolic blood pressure >100 mmHg).
  17. Have a history or presence of respiratory, liver, kidney, hormonal, blood, or neurological disorders which may put the patient at risk when taking the study medication; or may interfere with the interpretation of data.
  18. Have a history or presence of cardiovascular disorder within the last year, or signs of congestive heart failure, or are expected to require coronary artery bypass surgery or angioplasty.
  19. Have a history or presence of pancreatitis or certain gastrointestinal disorders.
  20. Have been exposed to radiation from clinical trials and from diagnostic X-ray or are exposed routinely via your job worker.
  21. Have any non-removable metal objects such as metal plates, screws etc. in their chest or abdominal area.
  22. Have had acute diarrhea or constipation within 14 days of study screening.
  23. Show evidence of significant active neuropsychiatric disease.
  24. Regularly use known drugs of abuse and/or show positive findings on urinary drug screening.
  25. Intend to start new medication during the study, including over-the-counter and herbal medication.
  26. Have donated blood of more than 500 milliliter (mL) within the last month prior to screening.
  27. Have an average weekly alcohol intake that exceeds the study centre's guidelines and are unwilling to adhere to the alcohol restrictions in place throughout the study.
  28. Smoke more than 10 cigarettes (or equivalent in nicotine) per day, and are unwilling to stop smoking on the day of medication administration or are unable to abide by clinical research unit (CRU) restrictions on other inpatient days.
  29. Are allergic to eggs or other components of the meals to be served.
  30. Are patients who, in the opinion of the investigator, are in any way unsuitable to participate in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01215968

Locations
United Kingdom
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Glasgow, United Kingdom
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

No publications provided

Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT01215968     History of Changes
Other Study ID Numbers: 13598, 2009-017305-11, H9X-EW-GBDM
Study First Received: October 5, 2010
Results First Received: October 3, 2014
Last Updated: October 3, 2014
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on November 20, 2014